|Awarded On||November 15, 2023|
|Title||A Phase 1-2 clinical study to evaluate SR-8541A plus balstilimab and botensilimab in MSS CRC patients|
|Program||Product Development Research|
|Award Mechanism||Texas Therapeutics Company Awards for Product Development Research|
|Institution/Organization||Stingray Therapeutics, Inc.|
|Principal Investigator/Program Director||Jonathan Northrup|
*Pending contract negotiation
Immune oncology therapeutics has created a revolution in treatment for patients. As wonderful as this progress is, it has still not led to cures for most people and more needs to be done. For example, checkpoint inhibitors have dramatically improved survival in melanoma (one of the best responding cancers) from 1-2 years to potentially 5-10. But after 5-10 years, survival is only 20% and most patients have succumbed to their cancer. Current immune oncology agents work in adaptive immunity. The other major arm of immunity, innate immunity, has not been enhanced with a therapeutic. We believe adding an agent that works to strengthen innate immunity and treating along with adaptive immunity mo...